On July 25, the biotech company Vizbiotech-B saw its shares open high on its first day of trading, rising nearly 130% at one point. The maximum profit per lot was HKD 4,460, and the total market value exceeded HKD 14 billion. The public offering was oversubscribed by a factor of 3,029, with the subscription amount reaching nearly HKD 340 billion. Among the subscribers, Futu had over 76,000 clients, with a subscription amount exceeding HKD 200 billion, ranking first in both the number of subscribers and the subscription amount in Hong Kong! The CNI Biomedicine Index has shown strong performance recently. Are you bullish on Vizbiotech's future growth?